Navigation Links
Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
Date:12/11/2009

OXFORD, England, December 11 /PRNewswire/ --

- Investment Follows Successful Phase Ii Clinical Results With cat Allergy T-cell Vaccine

- Funding to Progress ToleroMune(R) T-cell Allergy Vaccines Into Late-Stage Development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising. The investment follows recently announced positive phase II results with Circassia's ToleroMune(R) cat allergy T-cell vaccine. The financing will support the acceleration of the programme into late-stage development and advance the clinical development of Circassia's broader portfolio of novel allergy T-cell vaccines.

"The success of this funding round is a great vote of confidence in Circassia's unique allergy T-cell vaccine technology and the dedication of our team," said Steve Harris, Circassia's CEO. "Our most recent clinical results clearly demonstrate the potential of our ToleroMune(R) technology, as well as scientifically validating our novel use of T-cell vaccines to improve the treatment of allergy sufferers. This new investment recognises the importance of these results, and represents a strategic milestone in the development of Circassia's next generation allergy treatments."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's cat allergy T-cell vaccine show that short treatment regimes can greatly reduce patients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

About Circassia

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed three fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Invesco Perpetual, Goldman Sachs and Lansdowne Partners.

    For more information please visit http://www.circassia.co.uk.

    Contacts
    Steve Harris Rob Budge
    CEO RJB Communications
    Circassia Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241


SOURCE Circassia Ltd


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
2. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
3. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
4. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
5. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
6. Apnex Medical, Inc. Raises Additional $14 Million
7. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
8. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
9. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
10. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
11. Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):